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Abstract
Background: Components of the microenvironment such as bone marrow stromal cells (BMSCs) are well known
to support multiple myeloma (MM) disease progression and resistance to chemotherapy including the proteasome
inhibitor bortezomib. However, functional distinctions between BMSCs in MM patients and those in disease-free
marrow are not completely understood. We and other investigators have recently reported that NF-B activity in
primary MM cells is largely resistant to the proteasome inhibitor bortezomib, and that further enhancement of NF-
B by BMSCs is similarly resistant to bortezomib and may mediate resistance to this therapy. The mediating factor
(s) of this bortezomib-resistant NF-B activity is induced by BMSCs is not currently understood.
Results: Here we report that BMSCs specifically derived from MM patients are capable of further activating
bortezomib-resistant NF-B activity in MM cells. This induced activity is mediated by soluble proteinaceous factors
secreted by MM BMSCs. Among the multiple factors evaluated, interleukin-8 was secreted by BMSCs from MM
patients at significantly higher levels compared to those from non-MM sources, and we found that IL-8 contributes
to BMSC-induced NF-B activity.
Conclusions: BMSCs from MM patients uniquely enhance constitutive NF-B activity in MM cells via a
proteinaceous secreted factor in part in conjunction with IL-8. Since NF-B is known to potentiate MM cell survival
and confer resistance to drugs including bortezomib, further identification of the NF-B activating factors produced
specifically by MM-derived BMSCs may provide a novel biomarker and/or drug target for the treatment of this
commonly fatal disease.
Background
The non-cancerous cells associated with tumors were
recognized more than three decades ago to play consid-
erable roles in tumor development, progression and
maintenance [1]. Since then, there has been a significant
effort to delineate the specific contributions of these
cells to malignant cell behaviors. More specifically,
numerous recent studies have found that these suppor-
tive cells, although not cancerous per se, are functionally
and sometimes genetically different from their normal
counterparts [1]. Studies done in the nineties like those
by Cunha and colleagues in prostate cancer [2], and
Bissell and colleagues in breast cancer [3] have helped
to widen the focus of cancer researchers from just the
tumor cells to considering also the components around
them. As a result of this work, several cancer therapies
have been engineered specifically to target interactions
between tumor cells and their surrounding stroma [4].
Malignant plasma B cells characteristic of multiple
myeloma (MM) are also believed to rely heavily on their
interactions with elements of the surrounding microen-
vironment, including osteoclasts, osteoblasts, endothelial
cells, macrophages and bone marrow stromal cells
(BMSCs) [5]. Direct adhesive interactions between
B M S C sa n dm y e l o m ac e l l s ,a sw e l la sB M S Cs e c r e t i o n
of cytokines, chemokines, growth factors and other
components, contribute to a symbiotic cycle which
maintains a myeloma-promoting microenvironment and
* Correspondence: smiyamot@facstaff.wisc.edu
1Program in Cellular and Molecular Biology and Medical Science Training
Program, University of Wisconsin School of Medicine and Public Health, 750
Highland Avenue, Madison, Wisconsin, 53705, USA
Markovina et al. Molecular Cancer 2010, 9:176
http://www.molecular-cancer.com/content/9/1/176
© 2010 Markovina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.allows the tumor cells to thrive. These bidirectional
interactions disrupt the normal hematopoietic process,
induce osteolytic destruction of the bone, and contribute
to resistance to conventional therapies [5]. For example,
BMSC production of matrix proteins and factors such
as fibronectin [6], insulin-like growth factor-1 (IGF-1)
[7], stromal derived factor 1 alpha (SDF-1) [8], tumor
necrosis factor alpha (TNF-a), B cell activating factor
family (BAFF), and a proliferation inducing ligand
(APRIL) [5] have all been shown to promote MM cell
proliferation and resistance to conventional chemothera-
peutic agents. These discoveries have contributed to the
development of several recently approved targeted thera-
peutics, such as the proteasome inhibitor bortezomib,
and lenalidomide, that are believed to exert their anti-
MM effects at least in part by disrupting the interactions
between MM cells and the other cells in tumor micro-
environment [5,9].
MM is a complex and heterogeneous disease with
respect to clinical manifestations and drug responses.
Cytogenetic analyses and gene expression profiling stu-
dies further demonstrated the heterogeneity of MM
cells in different patients [10-14]. It remains unclear
how much of this complexity is due to differences in
MM-BMSC interactions in vivo. Several studies compar-
ing a small number of BMSCs from MM patients versus
healthy donors suggested that these non-malignant sup-
port cells were not significantly different [15-17].
Accordingly, it is generally considered that BMSCs affect
MM cells similarly, regardless of their specific sources.
However, analyses of a more extensive sampling of MM
and normal BMSCs exposed some important functional
and phenotypic distinctions of MM BMSCs [18-23]. In
particular, Wallace et al compared BMSCs from 8 MM
patients and 9 normal healthy donors and found
increased expression of both IL-1b and TNF-a by MM
BMSCs [21]. Arnulf and colleagues analyzed BMSCs
from 56 MM patients and 13 normal healthy donors
and found that BMSCs from MM patients not only
secreted higher levels of IL-6 than their normal counter-
parts, but also displayed an impaired ability to inhibit T
cell proliferation in functional studies [18]. MM BMSCs
have also been described to differentially express 145
distinct genes, about half of which are involved in
tumor-stroma cross-talk, induce higher proliferation of a
MM cell line, and are impaired in their ability to differ-
entiate into osteoblasts [24]. Garayoa and colleagues
recently analyzed BMSCs from 21 MM patients and 12
normal bone marrows for the presence of unbalanced
genomic alterations. They found that while all 12 nor-
mal BMSCs were free from genomic alterations, BMSCs
from 7 of the 21 MM patients displayed large gains or
losses, indicating that these cells are also often distinct
from their normal counterparts on a global genetic level
[ 2 5 ] .N o n e t h e l e s s ,o u ru n d e rstanding of the functional
distinctions between BMSCs of diseased and non-
diseased bone marrow is still incomplete.
The Rel/NF-B family of transcription factors has
been shown to play a pivotal role in the pathogenesis of
many human cancers, including MM [12,26,27]. NF-B
is constitutively active to variable levels in primary and
established MM cells, and has been shown to further
increase in activity in response to a number of factors
found in the bone marrow microenvironment
[10,11,28,29]. For example, adhesion of myeloma cell
lines to fibronectin results in increased NF-BD N A -
binding and correlates with induction of NF-B-regu-
lated genes [6]. IGF-1, which is secreted into the bone
marrow milieu, induces NF-B activity in MM cells, and
inhibition of IGF-1 binding to its receptor induces apop-
tosis of MM cells [7]. Similarly, SDF-1 induces transient
NF-B DNA-binding activity in some primary MM cells
[8]. Other well-known NF-B inducers including TNF-
a, IL-1b, BAFF, and APRIL are also present in the bone
marrow [5].
NF-B activation typically relies on two major path-
ways, canonical and noncanonical, involving degradation
and processing of the inhibitor IB and the precursor
p100, respectively, via the ubiquitin-dependent protea-
some pathway [30]. As such, both constitutive and indu-
cible NF-B activity in MM cells is generally believed to
be highly sensitive to inhibition by the proteasome inhi-
bitor bortezomib. This NF-B inhibitory activity of bor-
tezomib has been largely implicated in the clinical
efficacy of this drug against MM and another B cell
malignancy, Mantle Cell Lymphoma (MCL) [31]. In
contrast to this view, we and others have recently
shown that constitutive activity in primary MM cells is
largely resistant to bortezomib [32,33]. Similarly, we also
found that constitutive NF-B activity in many primary
MCL samples also showed bortezomib-resistance [34].
These studies indicated that primary MM and MCL,
and possibly other cancer cell types, may behave differ-
ently than expected from cell line-based studies. Since
NF-B activity in MM is also dependent on the bone
marrow milieu, whether NF-B activation in primary
MM cells through many of these microenvironment
interactions is effectively prevented by bortezomib still
remains an open question.
We previously showed that BMSCs generated from a
few MM patients induced NF-B activity in some pri-
mary and established MM cells. This activation is largely
resistant to bortezomib and confers resistance to borte-
zomib-induced apoptosis [33]. In the present study, we
expanded this analysis by examining BMSCs derived
from marrows of a cohort of MM patients and those
without MM pathology. Collectively, we found that
MM-associated BMSCs are functionally different from
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resistant NF-B activity in MM cells.
Results
BMSCs from MM patients are functionally distinct in their
ability to activate NF-B in MM cells
Because we have previously found that co-culture with
MM BMSCs can activate NF-B in the RPMI8226 MM
cell line and a few primary MM samples in a manner
that is largely resistant to bortezomib [33], we wanted
to know (i) how variable this response is among BMSCs
derived from different MM patients, and (ii) whether
BMSCs derived from normal marrow possess similar
NF-B-inducing activities. To this end, we derived pri-
mary BMSC cultures from 25 patients with diagnosed
MM, and from 21 normal marrows. Comparative analy-
sis of cell surface marker expression characteristic of
BMSCs showed few statistically significant differences
(Figure 1A). Confirming previous reports, we found that
CD54, also known as inter-cellular adhesion molecule-1
(ICAM-1), was heterogeneously expressed on the surface
of MM-BMSCs, but very little on non-MM BMSCs [20].
Expression of other markers was similar to that pre-
viously reported in the literature. We were then inter-
ested in the potential functional differences, and first
employed RPMI8226 and U266 established MM cell
lines to measure the differential effects of MM or non-
MM BMSCs on NF-B activation. Confirming our pre-
vious data [33], when co-cultured with BMSCs from
MM patients NF-B activity in RPMI8226 was enhanced
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Figure 1 BMSCs from MM patients selectively activate NF-B in RPMI8226 cells and primary MM cells. (A) Flow cytometric analysis
comparing expression of cell-surface markers on MM-patient derived (black dashed-line) and normal bone marrow-derived (grey filled curves)
BMSCs (isotype controls solid black). Curves shown are representative of eight BMSCs analyzed (four MM and four normal BMSC). The mean
percentage positive cells with standard deviations are presented in the table. (B) EMSA analysis of NF-B( " B”), STAT3 ("STAT3”) and Oct-1 ("Oct-
1”) DNA-binding in RPMI8226 cells cultured either alone or with BMSCs from the indicated MM patients for 24 hours. The two major NF-B
dimers active in RPMI8226 cells (p65-containing: one asterisk; RelB-containing: two asterisks) are labeled, and fold-change in NF-B DNA-binding
as measured by phosphoimage quantification is labeled below the B gel. (C) Similar EMSA analysis of RPMI8226 cells cultured alone or with
BMSCs from the indicated non-MM patients for 24 hours. (D) Fold-change in NF-B activity in RPMI8226 cells induced by various MM-BMSCs
("MM”) and non-MM BMSCs ("non-MM” and “MCL”), applied to a linear color gradient representing the range displayed as “Key.” (E) NF-B EMSA
of RPMI8226 cells cultured alone or with BMSCs from the indicated patients, that had been cultured for the indicated number of passages. (F)
Primary CD138
+ cells from the indicated patients were cultured alone or with BMSCs derived from the indicated MM patients, and then
subjected to EMSA analysis with B DNA-probe, or Oct-1 DNA-probe as a control. The main NF-B dimers are labeled as compared to
constitutive DNA-binding activity in RPMI8226 cells ("8226”). 100 nM bortezomib was added for the last four hours of co-culture where indicated
("Bort”).
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with the U266 cell line (data not shown). We chose to
further pursue this phenomenon in the RPMI8226 cell
line, because the constitutive level of NF-B activity is
so high in the U266 cell line, a 1.5-fold change in activ-
i t y( l i k ew es a ww i t hM M - B M S Cc o c u l t u r e )t h o u g h
likely functionally significant, is difficult to measure
robust changes in already high activity as measured by
electrophoretic mobility shift assay. We have previously
shown that our method of co-culture and cell-separation
for analysis represents only NF-B activity in the MM
cells and that the measured NF-B activity is not appre-
ciably contaminated by BMSCs [33]. Surprisingly,
BMSCs from non-MM patients largely did not affect
NF-B in these cells (Figure 1C). We observed striking
heterogeneity in the degree of NF-B activity induced
by BMSCs from different MM patients, spanning from
very little change to 6-fold increase in DNA-binding
activity (Figure 1D, Additional File 1). The observed dif-
ference in fold-induction of NF-B between the MM
and non-MM groups was highly statistically significant
(p = 0.001, Additional File 1). The two exceptions to
this trend were BMSCs derived from patients with
MCL, a B-cell malignancy that has many similarities to
MM, including frequent involvement of the bone mar-
row [33]. Omission of the four MCL patients from the
analysis revealed an even stronger difference statistically.
Furthermore, the degree to which BMSCs from a given
patient enhanced NF-B activity in MM cells remained
extremely stable within up to 8 passages in culture after
removal from the patient (Figure 1E). This suggests that
the specific ability of MM BMSCs to functionally affect
MM cells is an inherent property of the BMSCs them-
selves and is maintained during culturing. As a positive
control to demonstrate a general function of BMSCs, all
of them, regardless of MM or non-MM source, were
capable of robustly activating STAT3 DNA-binding
activity in RPMI8226 cells ([28,35], Figure 1B and 1C),
likely mediated by the significant levels of IL-6 secreted
by both types of BMSCs (see below).
Co-culture experiments with primary MM cells from
one patient and BMSCs from another patient assumedly
introduces unknown variables. Nevertheless, we were
interested to see if this differential ability of MM-
derived BMSCs to activate NF-Ba c t i v i t yw a sa l s ot r u e
in primary MM cells. To control for the variability in
constitutive NF-B activity between patients, the change
in NF-B activity after co-culture was normalized to the
level of constitutive activity in the MM cells from the
same patient, and all values were normalized to Oct-1
DNA-binding. These analyses demonstrated that BMSCs
often activated NF-B in primary MM (Figure 1F) but
those from normal marrow frequently did not (Addi-
tional File 2). However, the heterogeneity of inter-
patient experiments (i.e., the sources of MM cells and
BMSCs coming from different patients) or small sample
size failed to show statistical significance for the
observed differences. As previously shown [32,33], bor-
tezomib treatment often caused paradoxical increases in
NF-B activity in primary MM cells, showing that borte-
zomib-induced NF-B activation, rather than inhibition,
is a more common phenomenon, even in the presence
of MM BMSCs (Figures 1F).
To corroborate biochemical data based on EMSA ana-
lysis to a more functional readout, we next examined
the induction of a B-dependent GFP reporter in
RPMI8226 cells in the presence of BMSCs. The B-GFP
reporter construct was transiently transfected into
RPMI8226 cells which were then placed on BMSCs, or
exposed to TNFa a sap o s i t i v ec o n t r o l .W eo b s e r v e d
induction of B-dependent GFP activity similar to that
seen with TNFa treatment specifically by MM BMSCs,
and not normal BMSCs (Figure 2A and 2B). The
observed differences in the percentage of GFP-expres-
sing cells was highly statistically significant (p = 0.001,
Figure 2C). These studies revealed the previously unap-
preciated ability of MM BMSCs, but not non-MM
BMSCs, to induce NF-B activity in MM cells.
MM BMSC-induced NF-B activity is mediated by a
polypeptide(s) secreted by BMSCs
To gain insight into the nature of the MM BMSCs-
derived factor(s) capable of inducing bortezomib-resis-
tant NF-B activity in MM cells, we next asked
whether direct contact between RPMI8226 cells and
BMSCs was necessary. We employed semi-permeable
Transwell inserts to disrupt direct cell-cell contact.
These inserts have 2 μMp o r e sw h i c hp r e v e n tm i g r a -
tion of cells, but allow diffusion of most small mole-
cules, such as cytokines and growth factors. We found
that a transwell insert did not significantly inhibit NF-
B activation in RPMI8226 cells induced by BMSCs or
the positive control TNFa (Figure 3A). This result
demonstrated that physical contact between MM cells
and BMSCs is not necessary for NF-B activation and
that a soluble secreted factor(s) from BMSCs was med-
iating NF-B activation. This notion was further corro-
borated by our observation that CM from MM-BMSCs
was also able to activate NF-B in RPMI8226 cells and
primary MM cells (Figures 3B and 3C, respectively),
and concentration of the CM by size-exclusion with a
cut-off at 3 kDa resulted in further induced NF-B
activity (Figure 3B). Finally, the ability of BMSC CM to
activate NF-B activity in MM cells was abrogated by
pre-treatment of the CM with proteinase K and by
heating (Figure 3D), but not by DNase or RNase (not
shown). Importantly, the soluble factor(s) present in
CM from MM-BMSCs induced NF-B activity via a
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These results indicate that BMSC-induced NF-B
activity in MM cells is mediated by a soluble secreted
factor that is proteinaceous in nature and greater than
3k D a .
A number of BMSC-produced protein factors have
been shown to be important in MM pathogenesis, some
of which can activate NF-B in MM cells. Therefore, we
wanted to know whether a factor (or factors) well-
known to be produced by MM BMSCs was mediating
bortezomib-resistant NF-B activation in MM cells. To
this end, a neutralizing antibody against TNFa,w h i c h
was capable of blocking NF-B activity induced by
recombinant TNF-a in MM cells, did not block BMSC-
induced NF-B activity (Additional File 3A). This is
consistent with the observation that TNF-a-induced
canonical NF-B activation is highly sensitive to inhibi-
tion by bortezomib in contrast to the factor that we
were aiming to identify. SDF-1a (CXCL12), a factor that
i sb e l i e v e dt oc o n t r i b u t et ot h em a i n t e n a n c eo fM M
cells in the bone marrow, as well as to drug resistance
and proliferation of the tumor cells [8], did not induce
NF-B activity in RPMI8226 cells (Additional File 3B).
Additionally, a neutralizing antibody against SDF-1a
also did not block BMSC-induced NF-BD N A - b i n d i n g
activity in these cells (Additional File 3B). Similarly, a
neutralizing antibody against IGF-1 receptor, whose liga-
tion by IGF-1 has been shown to activate NF-Bi nc e r -
tain MM samples [29], had no effect on BMSC-induced
NF-B activity in RPMI8226 cells (Additional File 3B).
Moreover, IL-6, another important factor in MM growth
and survival, which is secreted at very high levels by
Figure 2 BMSCs from MM patients specifically induce expression of a B-dependent GFP reporter gene. (A) Representative 20× image of
RPMI8226 cells after transient transfection with a B-GFP reporter construct that were cultured alone or treated with 1 ng/mL of TNF-a for 24
hours, visualized either through a GFP filter ("GFP”), or phase contrast ("Phase”). (B) Similar representative images of RPMI8226 cells transiently
expressing the B-GFP reporter that were cultured either alone or with BMSCs from the indicated MM or non-MM patients for 24 hours. (C)
Quantification of the percentage of GFP-expressing cells ("% Green Cells”) over total live cells with n = 3 for each co-culture condition or TNF-a
treatment ("T”). Standard deviation is indicated by error bars and the p-value derived from statistical comparison of GFP expression induced by
co-culture with non-MM versus MM BMSCs.
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RPMI8226 cells (Additional File 3C).
BAFF and APRIL have been shown to be important in
MM pathogenesis and can stimulate noncanonical NF-
B activation; however, we found that neither the levels
of BAFF and APRIL mRNA or protein secreted from
BMSCs correlated with their ability to induce NF-B
(Additional File 3D). In fact, APRIL protein levels were
statistically significantly higher in the normal BMSC
group (Additional File 3D). Collectively, these data indi-
cate that the factor produced by MM BMSCs that is
responsible for bortezomib-resistant NF-B activation is
likely distinct from these well-known BMSC products.
IL-8 is a permissive factor for NF-B activation in MM
cells induced by some MM-BMSCs
To gain further insight into the nature of the BMSC-
secreted factor capable of inducing bortezomib-resis-
tant NF-B activity, CM was collected from 17 MM-
BMSCs and 13 non-MM BMSCs and a cytokine array
was used to simultaneously measure protein levels of
27 human cytokines in each sample (Additional File 4).
Median values for the MM and non-MM BMSCs are
displayed for each of the 27 cytokines, grouped by
relative range (Figure 4A). T h e s ec y t o k i n ea r r a yd a t a
showed that IL-8 was the only cytokine produced at
statistically significantly higher levels by MM-BMSCs
(p = 0.05, Figure 4A). Therefore, we next asked if IL-8
was involved in BMSC-induced NF-Ba c t i v i t yi n
RPMI8226 cells. IL-8 has not been previously shown
to cause NF-B activation in MM cells. Concordantly,
when we exposed RPMI8226 cells to recombinant
human IL-8 at various concentrations, we did not
observe any evidence of NF-Ba c t i v a t i o n( F i g u r e4 B ,
top panel), suggesting that IL-8 alone is insufficient to
cause NF-B activation. In contrast, use of anti-IL-8
neutralizing antibody in the context of co-culture
experiments resulted in partial inhibition of NF-B
a c t i v i t yi n d u c e db ys o m ep a t i e n tB M S C s( F i g u r e4 B ,
bottom panel), suggesting that IL-8 may be necessary
for NF-B activation induced by certain BMSCs. These
data indicate that IL-8 collaborates with another factor
(s) produced by BMSCs to induce NF-B activity in
MM cells. Consistent with this, exogenous IL-8,
although unable to directly cause NF-B activity, was
capable of potentiating NF-B activation by some
BMSCs (Figure 4C). Collectively, our data show that
IL-8 is a novel factor that can potentiate NF-B activa-
tion induced by certain MM BMSCs.
We next wanted to further characterize the nature of
the unknown factor (or factors) capable of inducing bor-
tezomib-resistant NF-B activity in MM cells. However,
Figure 3 MM BMSC-induced NF-B activity is mediated by a secreted peptide factor.(A) EMSA of NF-B activity in RPMI8226 cells cultured
alone or with BMSCs from the indicated MM patients, either directly, or physically separated by a Transwell insert ("Transwell”). 10 ng/mL TNF-a
was placed either directly in RPMI8226 culture or below the Transwell insert as a positive control for membrane permeability. The black line
indicates a different exposure time for the same gel for TNF-a-treated samples in order to better visualize the very different levels of binding
activity. (B) EMSA of NF-B and Oct-1 DNA-binding activity in RPMI8226 cells treated with 1× conditioned media (CM) or the same CM
concentrated 2-fold (2×) or 5-fold (5×) for 24 hours. (C) EMSA of NF-B activity in primary MM cells treated with CM derived from BMSCs of the
indicated MM patients. (D) EMSA of NF-B and Oct-1 DNA-binding activity in RPMI8226 cells treated with CM that had been previously treated
with proteinase K ("P”), or heat ("H”) where indicated. RPMI8226 cells were treated with CM from Pt. 134, and 100 nM bortezomib was added for
the last 4 hours of culture where indicated ("B”). NF-B dimers are labeled as before.
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BMSCs precluded extensive biochemical purification of
the CM. Furthermore, the factor(s) responsible for NF-
B-inducing activity was found to be labile and lost with
freeze-thaw cycles and prolonged incubation at 4°C
(data not shown), prohibiting cumulative collection of
CM. In a set of pilot studies we investigated the effect
of mesenchymal stem cells (MSCs) derived from human
embryonic stem cells [36,37] on MM cells. These ESC-
derived MSCs express cell surface markers and possess
multilineage differentiation potential similar to normal
bone marrow MSCs [36]. Analysis of a H1 ESC-derived
MSCs showed these cells produced a factor (or factors)
capable of robustly inducing NF-B activity in MM cells
in a manner resistant to bortezomib treatment (Figure
5A and 5B). The NF-B inducing factor produced by
these MSCs was also found to be similarly labile as that
from MM-BMSCs and could be enriched by cation affi-
nity ion-exchange chromatography (Figure 5C). This
purification demonstrated that the responsible factor is
acidic at neutral pH. Importantly, NF-B activity
induced by these fractions was highly resistant to borte-
zomib (Figure 5D) even though the same high concen-
tration of bortezomib could effectively prevent NF-B
activation induced by TNF-a treatment (Figure 5E).
These studies show that these human ESC-derived
MSCs could be a good source for purifying a novel
acidic factor that induces NF-B activity in a
Figure 4 IL-8 is differentially expressed by MM BMSCs and can potentiate BMSC-induced NF-B activity in RPMI8226 cells. (A) Median
levels of 27 cytokines measured by cytokine array analysis in CM from 17 MM BMSCs (white bars) and 13 non-MM BMSCs (black bars). The scale
is in pg/mL, and cytokines are grouped by relative concentration. Asterisk above IL-8 indicates a statistically significant difference between the
groups determined by Mann-Whitney test. (B) NF-B EMSA analysis of RPMI8226 cells treated with increasing doses of human recombinant IL-8
(top panel), and cultured alone or with BMSCs from the indicated patients with increasing amounts of anti-IL-8 neutralizing antibody as
indicated (bottom panel). (C) EMSA analysis of NF-B DNA-binding activity in RPMI8226 cells cultured alone or with BMSCs from the indicated
patients with various concentrations of recombinant human IL-8. Oct-1 controls, NF-B dimers, and fold-change in NF-B activity was quantified
and labeled as before.
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rently ongoing in our laboratory.
Discussion
The tumor microenvironment is thought to participate
in many aspects of human cancer. In MM, BMSCs and
the factors and matrix that they produce are important
in tumor cell proliferation and drug resistance. NF-B
has been implicated in this dynamic MM cell-stromal
communication and several components along the NF-
B signaling pathway are frequent targets of genetic
modification leading to constitutive activity in MM cells
[10,11], further supporting the important role that this
signaling system plays in MM pathogenesis. In addition,
NF-B activation in non-malignant BMSCs leads to
increased expression of cytokines and growth factors
such as IL-6, TNF-a, and VEGF [5], which can further
increase NF-B activity in MM cells. This NF-B activa-
tion in both MM cells and BMSCs is proposed to create
positive feedback loops to promote symbiotic interac-
tions and survival of MM cells in the bone marrow.
However, BMSCs from MM patients are generally con-
sidered to be indistinct from those in a normal healthy
individual, with the potential consequence of overlook-
ing novel drug targets and/or markers of disease that
are features specifically of MM-BMSCs.
We have previously shown that BMSCs from MM
patients variably activate NF-B in several MM cell lines
and primary MM cells in a manner that is resistant to
bortezomib. In the present study we addressed how
BMSCs from MM patients and normal marrow differen-
tially affect NF-B activity in MM cells. We employed
the MM cell line RPMI8226 to examine the functional
difference between a large cohort of patient-derived
MM and non-MM BMSCs. MM-BMSCs were found to
cause NF-B activation in these cells with a strong sta-
tistical significance over those from morphologically
normal marrow. The NF-B-inducing activity of the
BMSC cultures did not change over 8 passages in cul-
ture. This indicated that the phenotype of BMSCs with
respect to this functionality is quite stable in culture
and therefore reflects an intrinsic property, rather than
dependence on continual interaction with primary MM
cells. Thus, our study represents the first instance in
which MM-BMSCs were shown to possess an intrinsic
a n ds t a b l ed i f f e r e n c ef r o mt h o s eo fn o n - m y e l o m am a r -
row with respect to activation of NF-B.
The more consistent expression of CD54 (ICAM-1) on
M MB M S C si so fu n k n o w ns i g n i f i c a n c e .N o b o r i o -
Hatano and colleagues showed that downregulation of
CD54 expression on MM cells using short-hairpin RNA
decreased cell-adhesion mediated drug resistance of
MM cells to bortezomib [38]. It is possible, in a similar
sense, that disrupting the ICAM-1 (on BMSCs) -LFA-4
or -Mac-1 (on MM cells) interaction could also lead to
increased susceptibility of MM cells to bortezomib.
More extensive studies are required to test this
hypothesis.
To extend our findings with MM cell lines, we also
analyzed the effect of various BMSCs on primary MM
cells isolated from different patients and found a trend
analogous to RPMI8226 cells. These primary cell studies
were complicated, however, by multiple confounders.
First, constitutive levels of NF-B activity in primary
MM cells are quite variable from patient to patient.
Thus, if MM cells from a given patient have nearly
undetectable NF-B activity, any increase in DNA-
Figure 5 Partial purification of NF-B-inducing factor derived
from MSCs. (A) EMSA analysis of RPMI8226 cells cultured alone or
with H1-ESC-MSCs (ES-MSCs) for 24 hours with or without 4-hour
treatment of 100 nM bortezomib (Bort). (B) EMSA analysis of
RPMI8226 cells cultured alone or with CM from H1-ESC-MSCs (CM)
for 24 hours with or without 4-hour treatment with 100 nM
bortezomib (Bort). NF-B dimers and fold-change in DNA-binding
activity are displayed as before. (C) EMSA analysis of RPMI8226 cells
untreated (OT) or treated with 1× CM or sequential fractions eluted
from anion-exchange column with increasing NaCl concentration
gradient (Fraction 1-8). (D) EMSA analysis of RPMI8226 cells
untreated or treated with increasing aliquots of an activity-
containing fraction eluted from the anion-exchange column (Fr3),
with or without treatment with 100 nM bortezomib (Bort). (E) EMSA
analysis of RPMI8226 cells treated with 100 nM bortezomib (bort),
10 ng/mL rhTNF-a (TNF-a) or both.
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a small increase in MM cells that already harbor a very
high basal activity might have a significant functional
impact even though the fold-change may seem inconse-
quential when represented graphically. Second, the cur-
rent experimental set up necessitates that primary MM
cells from one patient are placed on BMSCs derived
from another patient, i.e., “inter-patient” analysis. This
design introduces an unknown level of complexity,
which can only be avoided by performing “intra-patient”
experiments. Currently, intra-patient experiments
require cryopreservation of primary MM cells during
t h ed e r i v a t i o no fB M S C sf r o mt h es a m ep a t i e n t ,ap r o -
cess which takes weeks beyond the viability of primary
MM cells in culture. Finally, the unknown effect of che-
motherapeutic agents on the microenvironment, and the
heterogeneity of the biopsy material, due to factors such
as location and timing during treatment on MM and
BMSC sampling introduce additional confounding com-
plexities to such analyses. Therefore, one of the major
future challenges is to develop strategies to overcome
such logistical issues and develop intra-patient experi-
mental strategies to further reveal mechanisms relevant
to individual MM patients at different points in their
treatment course. We also were not able to correlate
our findings in any way to patient characteristics, dis-
ease stage, or response to therapy because the samples
used in these studies were collected under an IRB-
exempt protocol. Future studies will be performed with
samples that have accompanying patient information in
order to obtain maximal insight about MM pathology.
NF-B is thought to have a significant role in MM
pathogenesis, and we have shown that bortezomib-resis-
tant NF-B activity correlates with cellular resistance to
bortezomib in vitro [33]. Therefore, identification of a
novel factor(s) produced by BMSCs that activates this
transcription factor could potentially provide a novel
biomarker or therapeutic target. Although key compo-
nents found in the marrow, such as TNF-a,S D F - 1 ,
IGF-1, IL-6, BAFF, and APRIL, are involved in MM
pathogenesis, we did not find evidence that these factors
were necessary for BMSC-induced, bortezomib-resistant
NF-B activity in MM cells. Some of these (IL-1b, TNF-
a, IL-6, and IL-8) have been described to be produced
at significantly higher levels by MM BMSCs than their
normal counterparts [18,20-22]; however, cytokine array
analysis of our BMSC cohorts detected a statistically sig-
nificant difference of only IL-8. A recent study compar-
ing production of IL-8 by BMSCs derived from patients
with monoclonal gammopathy of undetermined signifi-
cance (MGUS), an asymptomatic disease of increased
immunoglobulin secretion by plasma cells, smoldering
MM, or active MM, found that IL-8 levels correlated
positively with disease state [39]. In addition to its pro-
angiogenic effects in MM [40], our data suggest the pos-
sibility that IL-8 is also a contributing factor to increase
NF-B activity in some patients. Although our cytokine
a r r a yd a t as u g g e s tt h a tt h em a j o r i t yo fs o l u b l eI L - 8i s
being secreted by BMSCs, MM cells themselves can
secrete IL-8 and may contribute to this phenomenon in
an autocrine fashion.
MM-BMSCs are producing an additional factor (or
factors) that together results in a strong signal to acti-
vate NF-B in MM cells. This does not require direct
contact between BMSCs and MM cells. The responsible
factor(s) is sensitive to treatment with proteinase K and
heat, and can be concentrated with a 3 kDa cut-off, sug-
gesting that the factor(s) is a polypeptide of greater than
3 kDa. Because this BMSC-secreted factor causes NF-B
activation in MM cells in a manner resistant to bortezo-
mib [33], this would also represent the first known fac-
tor to induce proteasome inhibitor resistant (PIR) NF-
B activation in MM cells. The signal transduction
pathway leading to PIR NF-B activation in B cells is
not completely understood, although we have described
several critical events, including the role of calcium and
calmodulin [41-43]. Efforts to isolate and identify the
responsible factor from MM patient BMSCs were lim-
ited by their heterogeneity and the limited amount of
conditioned media obtained from these cells. Therefore,
we employed an H1-ESC-derived MSC line which also
produces a factor (or factors) that caused bortezomib-
resistant NF-B activity in MM cells for initial purifica-
tion studies. We were able to enrich this factor by ion
exchange chromatography. Further purification steps are
required to distil and identify the responsible factor(s).
Conclusions
Our findings and others’ indicate that the BMSCs in
patients with MM are functionally distinct from those in
normal marrow, the implications of which are not fully
understood. Because of the differentially ability of MM
BMSCs to uniquely induce the bortezomib-resistant NF-
B pathway, we have reason to believe that further
investigating into exactly how BMSCs differ in MM
patients could lead to improved understanding of MM
and therefore improved treatment of MM patients.
Identification of the MM BMSC factor would not only
permit further dissection of this putatively novel NF-B
signaling pathway in MM, but also could provide useful
markers for drug resistance and/or potential drug tar-
gets to be used in conjunction with targeted therapies
such as bortezomib and lenalidomide. Because we also
observed a similar NF-B-inducing activity in some
BMSCs derived from MCL patients and bortezomib-
resistant activity is also prevalent in primary MCL sam-
ples [34], such a factor could also play a role in promot-
ing MCL pathogenesis. Thus, our significant future goal
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examine its role in MM and MCL pathologies.
Methods
Cell lines, antibodies, and chemicals
The RPMI8226 cell line was cultured as previously
described [33]. Bortezomib was commercially obtained
from Millennium Pharmaceuticals, Inc. (Cambridge,
MA) for experimental purposes, proteinase K was from
Promega (Fitchburg, WI), and human recombinant
TNF-a from Calbiochem (San Diego, CA). Recombinant
human SDF-1, IL-8, IL-6, anti-SDF-1 and anti-IL-8 neu-
tralizing antibodies were from R&D systems (Minneapo-
lis, MN). Anti-IGF-1R neutralizing antibody was from
Calbiochem (Darmstadt, Germany), and anti-TNF-a
antibody from Chemicon International (Temecula, CA).
Primary BMSCs and MM Cells
Primary human BMSCs were derived from de-identified
fresh whole bone marrow aspirates, under the University
of Wisconsin Institutional Review Board exemption pro-
tocol #M-2004-1315. MM patients had active disease at
the time of sampling, and “non-MM” patients were
determined to have morphologically normal marrow by
UW pathologists. Because the protocol by nature pre-
cludes collection of any identifying information, the
samples collected were only accompanied by diagnosis,
and no information regarding disease stage, treatment
history or treatment response. Mononuclear cells were
isolated from aspirates as detailed in the Miltenyi Midi-
MACS bone marrow mononuclear cell protocol and as
described previously [33]. Mononuclear cells isolated
from MM patient bone marrow aspirates were positively
sorted using anti-CD138 magnetic microbeads and the
MidiMACS cell sorting system following manufacturer’s
protocol (Miltenyi Biotec, Auburn, CA) to >95% purity
as determined by anti-CD138-PE staining and FACS
analysis, and cultured in 37°C/5%CO2 incubators in
BMSC media.
Human ESC-derived MSCs
MSCs were derived from the H1 human embryonic
stem cell (ESC) line as previously described [36]. These
cells were cultured in aMEM media (Invitrogen, Carls-
bad, CA, USA) containing 20% fetal bovine serum, 0.1
mM nonessential amino acid (NEAA), and 2 mM L-glu-
tamine (glu). For collection of CM, H1-ES-MSCs were
cultured in phenol red-free aMEM media supplemented
with only 0.1 mM NEAA and 2 mM glu.
Co-culture, transwell, and conditioned media (CM) assays
6×1 0
4 BMSCs per well were plated in 6-well dishes
and allowed to form an adherent monolayer over 24
hours. 10
6 RPMI8226 cells or 5 × 10
5 primary MM cells
were plated over the monolayer for an additional 24
hours and then MM cells were mechanically detached
from the stromal layer. The BMSC monolayer was
undisturbed. Where appropriate, 100 nM bortezomib
was added for the last 4 hours of co-culture. Neutraliz-
ing antibodies and/or recombinant proteins were added
at the initiation of co-culture and, in the case of neutra-
lizing antibodies, were pulsed every 6 hours for the
duration of co-culture.
For transwell experiments, a monolayer of BMSCs was
plated as described above, the Transwell insert (BD
Biosciences, San Jose, CA) was placed over the BMSCs,
and RPMI8226 cells placed within the insert.
BMSC CM was prepared by first washing pre-estab-
lished BMSCs twice with 1× PBS then incubating them in
serum free “BMSC media” for 48 hours. This media was
clarified by centrifugation at 13,000 × g for 1 minute. CM
was concentrated using Amicon Ultra Centrifugal Filter
Devices with a 3 kDa molecular weight cut off according
to manufacturer’s instructions (Millipore, Billerica, MA),
treated with 200 μg/mL proteinase K at 37°C for one hour
followed by deactivation with 0.1 mM phenylmethylsul-
phonyl fluoride, or heated to 100°C for 30 minutes and
then centrifuged for one minute at 13,000 × g.
Partial enrichment of human ESC-derived MSC-induced
factor
Conditioned media was prepared by culturing a conflu-
ent monolayer of human ESC-MSCs between 4 and 10
passages, washing the monolayer 2× with 1× PBS, and
culturing the cells in serum-free, phenol-red free aMEM
media with L-glutamine, penicillin/streptomycin, sodium
bicarbonate and non-essential amino acids. After 48-72
hours, this conditioned media was aspirated and centri-
fuged at 10,000 × g for 5 minutes to remove cellular
debris. A portion of the albumin (likely human, pro-
duced by the MSCs) was removed using Affigel Blue
(Bio-Rad) resin at 1:20 dilution by stirring at 4 degrees
for one hour, which did not appreciably affect NF-B-
inducing activity (data not shown). The conditioned
media was again centrifuged at 10,000 × g for 5 minutes
and vacuum filtered over a PVDF membrane with 2 μm
pores to remove resin and air bubbles. After equilibra-
tion at 4 degrees, the conditioned media was run onto a
1.0 mL Mono Q 5/50 GL (GE Life Sciences) anion
exchange column (IEX) at ~1.5 MPa with 20 mM TRIS-
HCl, pH 8.0 starting buffer to bind cationic molecules,
using a benchtop ÄKTA FPLC (Amersham) at 4°C.
Bound material was then eluted using a linear salt gradi-
e n tf r o m0 - 0 . 5MN a C lo v e r3 0c o l u m nv o l u m e s ,a n d
1.0 mL fractions were collected and assayed for NF-B-
inducing activity by treating RPMI8226 cells with
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hours and performing EMSA.
Electrophoretic mobility shift assays (EMSA)
EMSA for cell lines were performed as described pre-
viously [44], using double strand DNA probes with the
following sequences: B: 5′-TCAACAGAGGGACTCC-
GAGAGGCC-3′, Oct-1 [41], and STAT3: 5′-
CGGGAGGGATTTACGGGAAATGCTA-3′.F o rp r i -
mary MM cells, miniaturized EMSA ("mini-EMSA”) was
performed as previously described [33]. Briefly, approxi-
mately 100,000 CD138
+ cells were lysed in 5 μLo f
Totex extraction buffer and 1.5 μL of this extract were
used for each reaction in NF-Ba n dO c t - 1D N A - b i n d -
ing assays. NF-B binding was normalized to Oct-1
binding to control for equal protein loading.
GFP-reporter assay
B-dependent reporter assay was performed as
described previously [33].
Quantitative real-time reverse transcriptase-polymerase
chain reaction (qRT-PCR) and enzyme-linked
immunosorbent assay (ELISA)
For BAFF and APRIL ELISA assays, CM was collected
from BMSCs as described above, and frozen for later
batch comparison. 50 μL aliquots of CM were thawed
on ice, aliquoted in duplicate into a 96-well instant
BAFF ELISA plate, or APRIL ELISA plate (Bender Med-
Systems, Burlingame, CA), and processed according to
manufacturer’s instructions.
Total RNA was collected from 10
5 BMSCs from each
patient using Trizol reagent (Invitrogen, Carlsbad, CA),
used to make cDNA, and qRT-PCR performed on a
BioRad iQ5, with the following primers: BAFF: 5′-
GGGAGCAGTCACGCCTTAC-3′ (forward), 5′-
CTGGGGAGGATGGAAACACAC-3′ (reverse); APRIL:
5′-CTCTGCTGACCCAACAAACAG-3′ (forward), 5′-
TTTTCCGGGATCTCTCCCCAT-3′ (reverse); GAPDH:
5′-GAAGGTCGGAGTCAACGGATTT-3′ (forward), 5′-
GAATTTGCCATGGGTGGAAT-3′ (reverse).
Cytokine Array
CM from BMSCs was prepared as described above and
kept frozen at -80°C for later batch comparison. Ali-
quots of CM were thawed on ice and placed in duplicate
into a 96-well dish, and concentrations of 27 human
cytokines included in the Human 27-Plex Panel (Bio-
Rad, Hercules, CA, USA) were measured in each well
using the Luminex fluorescent bead-based multiplex
cytokine assay system (Bio-Rad, Hercules, CA, USA)
according to the manufacturer’s instructions. Data were
analyzed with the Bio-Plex Manager software program.
Flow Cytometry
Antibodies used were anti-CD31 Allophycocyanin
(APC), anti-CD45 Phycoerythrin (PE), anti-CD90 APC
(eBioscience, San Diego, CA, USA), anti-CD 54 Fluores-
cein isothiocyanate (FITC), anti-CD105 APC, anti-HLA-
A B CF I T C( I n v i t r o g e n ,C a r l s b a d ,C A ,U S A ) ,a n t i - C D 1 4
FITC, anti-CD29 PE, anti-CD34 APC, anti-CD44 PE,
anti-CD73 PE, anti-HLA-ABC FITC, anti-HLA-DR
FITC (BD Pharmingen, San Diego, CA, USA), IgG2a
FITC isotype control antibody, IgG1 PE isotype control
antibody, IgG1 APC isotype control antibody (Miltenyi
Biotech). For surface staining, cells were harvested by
trypsinization for two minutes at 37°C. After centrifuga-
tion, supernatant was aspirated then antibodies were
added and incubated for 30 min at 4°C in dark. Cells
were then washed with PBS containing 0.5% BSA and 2
mM EDTA. 100,000 cells per sample were analyzed
using a Accuri C6 flow cytometer (Accuri cytometers,
Ann Arbor, MI, USA), and FlowJo software version
7.2.5 (Tree Star, Ashland, OR, USA). BMSCs from 4
MM patients and 4 normal marrow were analyzed.
Statistical analysis
Fold-induction of NF-B activity was determined by
phosphoimage quantification of enhanced NF-B activ-
ity over constitutive activity, which was assigned an arbi-
trary value of one. Observed differences between MM
and non-MM BMSCs were assessed for statistical signif-
icance using either Student’s t-test or Mann-Whitney
test depending on whether the normality assumption for
the distribution of the data was reasonable (GFP expres-
sion, BAFF and APRIL protein levels, and the differen-
tial expression of 27 cytokines) or not (fold change in
NF-B activity and BAFF and APRIL mRNA levels). All
tests were performed as a two-sided test, and the
observed significance level, i.e. p-value, less than 0.05
was considered to indicate statistical significance of the
observed differences
Additional material
Additional file 1: Effect of MM-BMSCs on NF-B activity in
RPMI8226 cells. Fold-change in NF-B activity induced by BMSCs as a
group of either MM, non-MM including MCL patients, non-MM excluding
MCL patients, and MCL patients alone. Median fold change is labeled by
horizontal lines, with p-values determined by Mann-Whitney analysis
below.
Additional file 2: BMSCs from MM patients activate NF-Bi n
primary MM cells more than BMSCs from non-MM patients.( A )
Color heat map was generated with fold-change in NF-B activity in
primary MM cells induced by various MM-BMSCs ("MM”) and non-MM
BMSCs ("non-MM”), these numbers were applied to a linear color
gradient representing the range displayed as “Key.” (B) Fold-change in
NF-B activity induced in primary MM cells by BMSCs as a group of
either MM or non-MM patients. Mean fold change is labeled by
horizontal lines.
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Page 11 of 13Additional file 3: MM BMSC-induced NF-B activity is mediated by a
factor that is distinct from many known BMSC products. (A) NF-B
EMSA of RPMI8226 cells treated with TNFa and/or anti-TNFa neutralizing
antibody (left panel), or cultured alone or with BMSCs with the addition
of increasing concentrations of anti-TNFa neutralizing antibody as
indicated (right panel). (B) NF-B EMSA of RPMI8226 cells treated with
increasing concentrations of recombinant human SDF-1a (top left panel)
or RPMI8226 cells cultured alone or with BMSCs with the addition of
anti-SDF-1a or anti-IGF-1R neutralizing antibodies where indicated (top
right and bottom panels). (C) EMSA of NF-B DNA-binding in RPMI8226
cells treated with increasing concentrations of recombinant IL-6 as
indicated. NF-B dimers for A-C are labeled as before. (D) Relative mRNA
(left panels) and protein levels (pg/mL, right panels) measured by qRT-
PCR and ELISA, respectively, of BAFF and APRIL expressed by BMSCs
derived from the indicated MM and non-MM patients. Standard
deviations are represented by error bars for qRT-PCR with n = 3.
Additional file 4: Range and standard deviations of MM BMSC
secretion of many cytokines is greater than those of non-MM
BMSCs. Levels of cytokines measured in the cytokine array with
conditioned media from each BMSC in the MM (open circles) and non-
MM (closed circles) group. Cytokines for which the range and standard
deviation was greater in the MM group than the non-MM group are
indicated by single stars. Cytokines for which removal of a single outlier
point in the non-MM group makes the range and standard deviation
greater for the MM group are indicated with double stars.
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